Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Create your
podcast in
minutes
It is Free